Učitavanje...
Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
BACKGROUND: Effective systemic therapies for patients with progressive neuroendocrine tumours of lung or gastrointestinal tract are limited. We aimed to assess the efficacy and safety of everolimus in this patient population. METHODS: In RADIANT-4, a randomised, double-blind, placebo-controlled, pha...
Spremljeno u:
| Izdano u: | Lancet |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6063317/ https://ncbi.nlm.nih.gov/pubmed/26703889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00817-X |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|